Background: Despite the wide use of antitachycardia pacing (ATP) in patients with
implantable cardioverter defibrillators (ICDs), predictors of ATP success remain poorly …

The efficacy and safety of external programmable automatic antitachycardia pacemakers
(ATPs) used in the critical care setting for recurrent sustained monomorphic ventricular …

BACKGROUND: Antitachycardia pacing (ATP) can reduce implantable cardioverter-
defibrillator shocks, but its use in children and patients with congenital heart disease (CHD) …

Cardiac pacing has played a significant role in mitigating morbidity and mortality associated
with bradyarrhythmias. Throughout the years, advances made in battery reliability, lead …

Background Anti‐tachycardia pacing (ATP) delivered from an implantable device is a useful
tool to terminate ventricular tachycardia (VT). But its real‐world efficacy for those patients …

Antitachycardia pacing for the termination of ventricular tachycardia (VT) is a standard
feature of implantable cardioverter-defibrillators (ICDs). New generation tiered-therapy …

Objectives: The purpose of this study was to evaluate the effect of these therapies on
healthcare utilization in a large patient cohort. Background: Antitachycardia pacing (ATP) …

ICDs and Signal Analyses Introduction Antitachycardia pacing (ATP), a quick, painless, and
effective therapy available in implantable cardioverter‐defibrillators (ICDs), can terminate …

Introduction and objectives Fast ventricular tachycardias in the ventricular fibrillation zone in
patients with an implantable cardioverter-defibrillator are susceptible to antitachycardia …

Atrial fibrillation (AF) is the most common dysrhythmia in North America. Paroxysmal or
persistent AF affects an estimated 2.8 million individuals, causes significant morbidity, and is …